UNASSIGNED: 247 Background: Chemotherapy for @entity263 reduces PSA levels and enhances @entity1349 ( @entity1349 ), suggesting that administration in earlier disease stages may be beneficial. If expansion of an @entity342 -independent clone is present during @entity342 deprivation mediates the transformation from an @entity342 -dependent to an @entity342 -independent phenotype, combination chemohormonal therapy could be effective initial treatment for locally advanced or metastatic @entity263 . This study examined the efficacy and safety of chemohormal therapy approach. METHODS: @entity1 received medical castration plus an anti- @entity342 and chemotherapy (nab- @entity1311 , @entity3086 , @entity12195 ). @entity1 were followed with PSA levels and radiographic assessments. RESULTS: Forty-six @entity1 (median age) 64.7 years were treated. Fifty-eight percent underwent prior local therapy including prostatectomy (30%), prior radiation (15%), or both (13%). Median baseline PSA was 8.9 ng/ml, and 96% of @entity1 had a Gleason score of >= 7%. At 2 years, 78% of @entity1 experienced @entity5 regression with a median reduction in PSA level of >90%. Median time to progression was 28.43 months measured by PSA and 34.52 months measured radiographically. Median @entity1349 was 62.4 months. The most frequent significant adverse events included grade 3 @entity1371 (17%) and @entity2905 (59%). CONCLUSIONS: Combination chemohormonal therapy for locally advanced and metastatic @entity263 delayed disease progression and enhanced @entity1349 . Information presented will include curves and correlation detailing efficacy and adverse events of various sub-populations.

A phase II trial of chemotherapy plus hormone therapy as initial treatment of unresectable/metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men'] @entity3086 :: ('MESH:D016729', 'Chemical') :: ['leuprolide'] @entity12195 :: ('MESH:C053541', 'Chemical') :: ['bicalutamide'] @entity263 :: ('MESH:D011471', 'Disease') :: ['hormone-refractory prostate cancer', 'prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity2905 :: ('MESH:D008231', 'Disease') :: ['lymphopenia'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity263 :: (MESH:D011471,Disease) :: ['adenocarcinoma of the prostate']
